Clomipramine
Clomipramine is a tricyclic antidepressant specifically indicated for obsessive-compulsive disorder (OCD). It is considered one of the most effective treatments for OCD and is often preferred over other tricyclics due to its superior efficacy for obsessive-compulsive symptoms, though it has significant side effects that require careful monitoring.
Clinical Overview
Primary Clinical Applications
Clomipramine is the gold standard tricyclic for OCD treatment and has demonstrated superior efficacy compared to other tricyclics for this indication. It may also be used off-label for depression, panic disorder, and other anxiety disorders when OCD features are prominent.
Mechanism and Clinical Benefits
Clomipramine potently inhibits serotonin reuptake (more so than other tricyclics) in addition to norepinephrine reuptake. This dual mechanism, with particular serotonergic activity, accounts for its unique efficacy in OCD treatment. It also has significant anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
Clinical Considerations
Clomipramine requires gradual dose titration to minimize side effects, particularly gastrointestinal symptoms. It has a higher incidence of sexual side effects compared to other tricyclics and may cause significant weight gain. Therapeutic drug monitoring may be helpful to optimize dosing and minimize toxicity.
Key Clinical Points
The tricyclic of choice for OCD
Clomipramine is the only tricyclic with an OCD indication and has demonstrated superior efficacy for obsessive-compulsive symptoms compared with others in its class, reflecting its potent serotonergic activity.
Seizure risk rises above 250 mg
Seizure risk is dose-related and becomes clinically significant at the upper end of the range. This is the reason the maximum dose is capped at 250 mg daily in adults.
Sexual dysfunction affects adherence
Rates are higher than with other tricyclics and are a frequent, often unreported, cause of discontinuation. Asking directly rather than waiting for disclosure materially improves persistence on treatment.
Titrate slowly to manage GI effects
Reaching 100 mg daily over roughly two weeks, taken with meals and divided during titration, substantially reduces the nausea and dyspepsia that otherwise derail early treatment.
Boxed warning and MAOI contraindication
Carries the antidepressant boxed warning for patients under 25. Contraindicated within fourteen days of an MAOI and with linezolid or intravenous methylene blue. CYP2D6 inhibitors substantially raise levels.
Prescribing Information
Dosing & Administration
Obsessive-Compulsive Disorder – Adults:
- Initial: 25 mg daily at bedtime
- Titration: Increase gradually to 100 mg daily over 2 weeks
- Range: 100-250 mg daily
- Maximum: 250 mg daily
- Maintenance: Usually 100-150 mg daily
Children and Adolescents (≥10 years):
- Initial: 25 mg daily
- Titration: Increase gradually over 2 weeks to 3 mg/kg/day or 100 mg daily (whichever is smaller)
- Maximum: 3 mg/kg/day or 200 mg daily
Administration:
- Take with meals to reduce GI upset
- May give entire dose at bedtime once stabilized
- Divide doses during titration period
Indications
- Obsessive-compulsive disorder (adults and children ≥10 years)
- Off-label: Depression with OCD features, panic disorder
Contraindications
- Hypersensitivity to tricyclic antidepressants
- Use within 14 days of MAOI therapy
- Acute recovery period following myocardial infarction
- Concurrent use with linezolid or IV methylene blue
Warnings & Precautions
- Boxed Warning: Increased risk of suicidal thoughts and behavior in patients under 25 years
- Cardiovascular effects: Monitor ECG in patients with cardiac disease
- Seizure risk: Dose-related, particularly >250 mg daily
- Anticholinergic effects: Significant – dry mouth, constipation, urinary retention
- Sexual dysfunction: High incidence, may affect compliance
- Weight gain: Significant risk with long-term use
Drug Interactions
- MAOIs: Contraindicated – risk of serotonin syndrome
- CYP2D6 inhibitors: Significantly increase clomipramine levels
- CNS depressants: Enhanced sedation
- Anticholinergic drugs: Additive anticholinergic effects
- Type 1C antiarrhythmics: Additive cardiac effects
Adverse Reactions
Common (>10%):
- Dry mouth, constipation, nausea, dyspepsia
- Somnolence, dizziness, tremor, nervousness
- Sexual dysfunction, weight gain
Serious:
- Cardiac arrhythmias, seizures (dose-related), severe anticholinergic toxicity
Special Populations
- Elderly: Start with lower doses, monitor for anticholinergic effects
- CYP2D6 poor metabolizers: Require significantly lower doses
- Pregnancy: Category C – use only if benefits outweigh risks
- Therapeutic monitoring: May be helpful to optimize dosing
Frequently Asked Questions
What is Clomipramine used for?
Clomipramine is a tricyclic antidepressant specifically indicated for obsessive-compulsive disorder (OCD). It is considered one of the most effective treatments for OCD and is often preferred over other tricyclics due to its superior efficacy for obsessive-compulsive symptoms, though it has significant side effects that require careful monitoring.
What class of drug is Clomipramine?
Clomipramine is classified as: Tricyclic Antidepressant.
The tricyclic of choice for OCD?
Clomipramine is the only tricyclic with an OCD indication and has demonstrated superior efficacy for obsessive-compulsive symptoms compared with others in its class, reflecting its potent serotonergic activity.
Seizure risk rises above 250 mg?
Seizure risk is dose-related and becomes clinically significant at the upper end of the range. This is the reason the maximum dose is capped at 250 mg daily in adults.
Sexual dysfunction affects adherence?
Rates are higher than with other tricyclics and are a frequent, often unreported, cause of discontinuation. Asking directly rather than waiting for disclosure materially improves persistence on treatment.
Titrate slowly to manage GI effects?
Reaching 100 mg daily over roughly two weeks, taken with meals and divided during titration, substantially reduces the nausea and dyspepsia that otherwise derail early treatment.
Source: FDA prescribing information (DailyMed)